Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
NCT01672463
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Recurrent Malignant Glioma
Interventions
DRUG:
OKN-007
Sponsor
Oblato, Inc.